COMMUNICATION IS CRITICAL
Evidence suggests that breakdowns in the bladder-brain communication pathway are the root cause of OAB and non-obstructive urinary retention.1-3 While more conservative therapies focus on the bladder muscles, Medtronic therapies target the nerves, which is thought to help restore normal bladder function.*
THE RELIEF YOU’VE BEEN WAITING FOR
When lifestyle changes and medications fail, Medtronic bladder control therapy delivered by the InterStim™ systems can help. This therapy is simple and discreet, and it delivers the kind of relief that lets you enjoy the activities you love without a second thought.
THE CHOICE IS YOURS
Compare the InterStim™ II and InterStim™ Micro systems for Medtronic bladder control.
Implanting an InterStim™ system has risks similar to any surgical procedure, including swelling, bruising, bleeding, and infection. Talk with your doctor about ways to minimize these risks.
Medtronic bladder control therapy delivered by the InterStim™ II system provides life changing relief. And the InterStim™ Micro system is designed to deliver the same eﬀective results.
The most common adverse events experienced during clinical studies included pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.
The NURO™ system only treats the symptoms of OAB, not retention.
Most common side eﬀects of PTNM are temporary and include mild pain or skin inﬂammation at or near the stimulation site.MORE ABOUT PTNM
Deﬁned as a 50% or greater reduction in your troublesome bladder symptoms.
Numbers reﬂect completers analysis deﬁned as patients with diary data at baseline and 12 months (n=220). Clinical success was 82% at 12 months using the modiﬁed completers analysis (subjects who either had a baseline and 12 month evaluation or withdrew early due to device-related reasons and are considered failures).
Under certain conditions. See approved labeling for details. Patients with InterStimTM SureScanTM MRI leads only.
Battery life may vary based on therapy settings.
Under standard patient therapy settings and appropriate recharger placement.
Reﬂects OAB patients.
These patient groups were analyzed based on the treatment they were assigned: incomplete data was counted as ”failures.” Another analysis reported 61% of people achieved success with InterStim, compared to 42% who used medications.
Restored bladder function is deﬁned as a measurable reduction in urinary frequency and/or urinary incontinence episodes following treatment.
Dasgupta R, Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol. 2005;174:2268–2272.
Griﬃths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol. 2005;174:1862–1867.
Griﬃths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn. 2008;27(6):466–474.
Noblett K, Siegel S, Mangel J, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and eﬃcacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn. 2016 Feb;35(2):246-51.
National Association for Continence. Overactive Bladder. www.nafc.org/overactive-bladder. Accessed November 21, 2016.
Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim® Therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34:224–230.
Foster RT Sr, Anoia EJ, Webster GD, Amundsen CL. In patients undergoing neuromodulation for intractable urge incontinence a reduction in 24-hr pad weight after the initial test stimulation best predicts long-term patient satisfaction. Neurourol Urodyn. 2007;26:213–217.
Visco A, Brubaker L, Richter HE, et al. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. New Engl J Med. 2012;367(19):1803–1813.
Peters KM, Carrico DJ, et al. “Randomized trial of percutaneous tibial nerve stimulation versus Sham eﬃcacy in the treatment of overactive bladder syndrome: results from the SUmiT trial.” J Urol. 2010;183(4): 1438-1443.
Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055-1061.
Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.